Sprouting strategies and dead ends in anti-angiogenic targeting of NETs.

Related Articles

Sprouting strategies and dead ends in anti-angiogenic targeting of NETs.

J Mol Endocrinol. 2017 Jul;59(1):R77-R91

Authors: Carrasco P, Zuazo-Gaztelu I, Casanovas O

Abstract
Neuroendocrine tumors (NETs) are a heterogeneous group of neoplasms that arise from cells of the neuroendocrine system. NETs are characterized by being highly vascularized tumors that produce large amounts of proangiogenic factors. Due to their complexity and heterogeneity, progress in the development of successful therapeutic approaches has been limited. For instance, standard chemotherapy-based therapies have proven to be poorly selective for tumor cells and toxic for normal tissues. Considering the urge to develop an efficient therapy to treat NET patients, vascular targeting has been proposed as a new approach to block tumor growth. This review provides an update of the mechanisms regulating different components of vessels and their contribution to tumor progression in order to develop new therapeutic drugs. Following the description of classical anti-angiogenic therapies that target VEGF pathway, new angiogenic targets such as PDGFs, EGFs, FGFs and semaphorins are further explored. Based on recent research in the field, the combination of therapies that target multiple and different components of vessel formation would be the best approach to specifically target NETs and inhibit tumor growth.

PMID: 28469004 [PubMed - indexed for MEDLINE]

https://ift.tt/2uhbszB